Misr Pharma Company plans to achieve sales of 555 million pounds and net profits of 50 million pounds

We have successfully passed the SFDA inspection of Saudi Coli Urinal "Effervescent " and registered products at the Food and Drug Authority. Dr. Amal Abdel Karim, Chairman and Managing Director, indicated that the company plans to achieve sales of 375 million pounds in 19/20 and a net profit of 10 million pounds, to increase to 555 million pounds in sales and a net profit of 50 million pounds in 21/22.